Omentin-1 vs REGN1033
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and REGN1033 (Trevogrumab (REGN1033)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | REGN1033 |
|---|---|---|
| Category | Diabetes & Metabolic | Muscle & Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Trevogrumab (REGN1033) |
| Molecular Weight | ~35 kDa | ~150 kDa |
| Half-Life | hours | ~2-3 weeks |
| Amino Acids | 313 | N/A |
| Typical Dose | No approved human dose; research use only | 100-300 mg SC or equivalent trial dosing |
| Route | IV|SC | Subcutaneous / Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 60 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
REGN1033 Benefits
- ✓myostatin blockade
- ✓lean-mass preservation
- ✓muscle hypertrophy support
- ✓catabolic-state countermeasure
Omentin-1 Dosing
not established|not established
REGN1033 Dosing
SC or IV clinical-trial dosing|repeat every 2-4 weeks|dose escalation by study
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
REGN1033 Side Effects
- ⚠injection-site reactions
- ⚠headache
- ⚠fatigue
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
REGN1033
Human and animal studies indicate that myostatin neutralization can increase muscle size, though functional gains are often smaller than mass gains. Trevogrumab is part of the broader literature showing that selective myostatin inhibition can alter body composition in clinically meaningful ways.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.